Dentigenix Inc.

Discovery and development of therapies to regenerate dental tissue

Dentigenix Inc. is a wholly-owned subsidiary of Ivoclar-Vivadent, Inc. the world’s leading manufacturer of quality dental products.

Erick Rabins, COO, President
Bruce Rutherford, Dr., CSO
Jeanette Ennis, Dr., Intellectual Property Manager

Rutherford, PhD
Bruce J. Baum, PhD
William Giannobile
Paul Krebsbach, PhD
David Mooney, PhD
David H. Pashley, PhD
Tony Smith, Ph.D.
Malcolm Snead, Ph.D.
Phil Stashenko, Ph.D.
Irma Thesleff

454 North 34th Street
Seattle, WA 98103
USA
Phone: +1-206-547-4790
Fax: +1-206-547-4789

The company develops a family of dental tissue engineering products to treat and repair progressive destruction of tooth structure. The object is the preservation, repair or regrowth of natural dental tissue. Basically, the company has three programmes, the whole tooth regeneration programme intends to grow new permanent natural teeth as alternatives for conventional prosthetic devices such as dentures and dental implants, secondly, the company is developing two products, DTX.21 and DTX.DR-1 to induce dentin regeneration over vital pulp exposures (potential alternatives for up to 50% of root canal treatments), and thirdly, developing DTX.41 to improve the natural remineralisation process of teeth.